Fujirebio is launching a human cerebrospinal fluid (CSF) assay in its continuing efforts to detect Alzheimer’s ...

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th ...

A collaborative research team has developed the world's first AI-based optical diagnostic platform that enables rapid and ...

Chemotherapy for pediatric acute lymphoblastic leukemia (ALL) induces rapid and durable alterations in cerebrospinal fluid (CSF) metabolism, and a lipid-rich CSF signature measured early in treatment ...

A new breakthrough study from the Rotman Research Institute at Baycrest, University of Toronto (Motsenyat et al., Brain Stimulation 2025) shows that brief sessions of pulsed photobiomodulation (PBM) ...

Cerebrospinal fluid (CSF) leaks represent a significant clinical challenge, marked by the aberrant escape of CSF from its usual confines into adjacent structures such as the paranasal sinuses, which ...

Exploring the genetic blueprint of cerebrospinal fluid proteins, this study uncovers new markers and therapeutic targets that may unlock advancements in Alzheimer’s diagnosis and care. Study: ...

CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.